期刊文献+

生物制剂治疗类风湿关节炎的药物依从性研究 被引量:6

下载PDF
导出
摘要 类风湿关节炎(Rheumatoid Arthritis,RA)是一种常见的以关节组织慢性炎症性疾病为主要表现的自身免疫性疾病。病程中由于滑膜的慢性炎症和血管翳的形成,可侵蚀多个关节的骨和软骨组织,导致关节破坏,最终引起畸形和功能丧失。研究表明,未经正规治疗的RA患者致残率高,严重影响患者的工作能力和生活质量。近年来生物制剂的出现为RA的治疗带来了新的展望,但RA与其他慢性疾病一样,患者的药物依从性较差,而依从性是决定治疗成功,使患者达到长期疾病缓解的必要因素。因此,通过选择有效的治疗措施并且提高药物依从性,对于控制疾病的预后及并发症有重要意义。
出处 《中国处方药》 2017年第4期12-16,共5页 Journal of China Prescription Drug
基金 山西省卫生厅科研课题(201301014)
  • 相关文献

参考文献6

二级参考文献61

  • 1刘启华,王玉玲,张鹤,丁婷.护理干预对类风湿关节炎患者焦虑抑郁心理的影响[J].齐鲁护理杂志,2004,10(10):729-731. 被引量:40
  • 2童允洁,鲍松晴.健康教育对类风湿关节炎患者疗效及依从性的影响[J].现代医学,2007,35(2):150-151. 被引量:6
  • 3李大魁,张石革.药学综合知识与技能[M].北京:中国医药科技出版社,2011:1.
  • 4Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatie drugs: 2013 update[J]. Ann Rheum Dis,2014, 73: 492-509.
  • 5Maini R, Scalar EW, Breedveh F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant concomitant metho - trexate: A randomized phase m trial[J] . Lancet, 2011,354 (9194) : 1932 - 1939.
  • 6Nuki G, Bresniban B, Bear MB, et al. Long term safety and maintenance of clinical imprudent following treatment with anakinra ( recombinant hu - man interleulkin - 1 receptor antagonist) in patients with rheumatoid ar - thritis : extension phase of a randomized, double - blind, placebo - con - trolled trial[ J ]. Arthritis Rheum ,2012,46 ( 11 ) :2838 - 2846.
  • 7Saag KG, Teng GG, Patkar NM, et al. American College of Rheunma- tology 2008 recommendations for the use of no biologic and biologic dis- ease modifying ant rheumatic drugs in rheumatoid arthritis [ J] . Ar- thritis Rheum, 2011, 59 (13) : 762 -766.
  • 8Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituxlmab: a randomized, placebo - controlled trial in patients who are biological naive with acetive rheumatoid arthrifis and an inadequate response to methotrexatc Study Evaluating Rituximab"s Efficacy in MTXi Nadequater Esponders (SERENE) [ J ] . Ann Rheum -Dis, 2010, 69 (12): 1629-1635.
  • 9Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population[J]. J Manag Care Pharm, 2013, 19(8): 621-630.
  • 10Xu C, Wang X, Mu R, et al. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study[J]. Arthritis Care Res (Hoboken), 2014, 66(4): 523-531.

共引文献58

同被引文献41

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部